ABVC BioPharma (ABVC) Competitors $2.94 -0.02 (-0.51%) As of 01:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVC vs. ENGN, AVTE, IPHA, MDWD, GNFT, DMAC, EPRX, CTMX, CRBU, and ELDNShould you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include enGene (ENGN), Aerovate Therapeutics (AVTE), Innate Pharma (IPHA), MediWound (MDWD), GENFIT (GNFT), DiaMedica Therapeutics (DMAC), Eupraxia Pharmaceuticals (EPRX), CytomX Therapeutics (CTMX), Caribou Biosciences (CRBU), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry. ABVC BioPharma vs. Its Competitors enGene Aerovate Therapeutics Innate Pharma MediWound GENFIT DiaMedica Therapeutics Eupraxia Pharmaceuticals CytomX Therapeutics Caribou Biosciences Eledon Pharmaceuticals ABVC BioPharma (NASDAQ:ABVC) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability. Does the media refer more to ABVC or ENGN? In the previous week, ABVC BioPharma and ABVC BioPharma both had 4 articles in the media. ABVC BioPharma's average media sentiment score of 0.58 beat enGene's score of 0.40 indicating that ABVC BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABVC BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer ABVC or ENGN? enGene has a consensus target price of $23.29, suggesting a potential upside of 529.17%. Given enGene's stronger consensus rating and higher possible upside, analysts clearly believe enGene is more favorable than ABVC BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00enGene 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is ABVC or ENGN more profitable? enGene has a net margin of 0.00% compared to ABVC BioPharma's net margin of -963.46%. ABVC BioPharma's return on equity of -29.62% beat enGene's return on equity.Company Net Margins Return on Equity Return on Assets ABVC BioPharma-963.46% -29.62% -14.08% enGene N/A -32.60%-28.26% Which has more volatility & risk, ABVC or ENGN? ABVC BioPharma has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.41, suggesting that its stock price is 141% less volatile than the S&P 500. Do institutionals and insiders believe in ABVC or ENGN? 11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 17.1% of ABVC BioPharma shares are held by insiders. Comparatively, 10.4% of enGene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation & earnings, ABVC or ENGN? ABVC BioPharma has higher revenue and earnings than enGene. ABVC BioPharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioABVC BioPharma$510K97.72-$4.90M-$0.13-22.58enGeneN/AN/A-$55.14M-$1.65-2.24 SummaryABVC BioPharma beats enGene on 8 of the 15 factors compared between the two stocks. Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVC vs. The Competition Export to ExcelMetricABVC BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.75M$3.03B$5.50B$9.81BDividend YieldN/A2.28%4.59%4.13%P/E Ratio-22.5417.3829.9425.16Price / Sales97.72349.44445.68102.78Price / CashN/A40.7324.8128.01Price / Book48.928.988.685.82Net Income-$4.90M-$54.75M$3.26B$265.22M7 Day Performance-2.17%-0.94%0.61%0.75%1 Month Performance-26.07%7.33%3.33%1.97%1 Year Performance327.34%23.30%45.75%27.33% ABVC BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVCABVC BioPharma0.9922 of 5 stars$2.94-0.5%N/A+328.2%$49.75M$510K-22.5430Upcoming EarningsENGNenGene3.3277 of 5 stars$3.94+3.1%$23.29+491.0%-44.2%$201.33MN/A-2.3931AVTEAerovate TherapeuticsN/A$6.89-4.2%N/A-87.3%$199.71MN/A-2.3020News CoverageHigh Trading VolumeIPHAInnate Pharma2.559 of 5 stars$2.14+1.4%$11.00+414.0%-8.8%$197.27M$21.77M0.00220MDWDMediWound2.0289 of 5 stars$17.96-2.2%$32.25+79.6%+3.7%$194.11M$19.21M-8.5980Upcoming EarningsGNFTGENFIT1.2929 of 5 stars$3.88+2.3%$13.00+235.4%-5.1%$193.80M$76.77M0.00120DMACDiaMedica Therapeutics1.771 of 5 stars$4.49+3.0%$10.75+139.4%+29.0%$192.53MN/A-7.0220News CoverageHigh Trading VolumeEPRXEupraxia Pharmaceuticals2.7791 of 5 stars$5.35-0.5%$11.00+105.5%+98.5%$192.53MN/A-7.0429CTMXCytomX Therapeutics4.0065 of 5 stars$2.37-0.8%$5.75+142.6%+92.5%$191.07M$138.10M4.94170Analyst RevisionGap DownCRBUCaribou Biosciences2.4841 of 5 stars$2.04-2.9%$8.50+316.7%-11.9%$189.72M$9.99M-1.26100ELDNEledon Pharmaceuticals1.7024 of 5 stars$3.13-3.7%$10.00+219.5%+3.4%$187.42MN/A-1.4910News CoverageUpcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies enGene Competitors Aerovate Therapeutics Competitors Innate Pharma Competitors MediWound Competitors GENFIT Competitors DiaMedica Therapeutics Competitors Eupraxia Pharmaceuticals Competitors CytomX Therapeutics Competitors Caribou Biosciences Competitors Eledon Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVC) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | Sponsored#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredSilver Demand Is Exploding—and Supply Can’t Keep UpElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.